Paul Chaplin steps down as Bavarian Nordic CEO
Danish vaccine maker Bavarian Nordic (OMX: BAVA) announced today, that the board of directors has entered into an agreement with chief executive (CEO), Paul Chaplin, who wishes to step down for personal reasons.
Mr Chaplin will continue in his role for the remainder of 2026, or until a successor has been identified. The board of directors has initiated the process to identify a new CEO. The firm’s shares dipped 2% on the news.
His departure comes after the company’s $3-billion take-private deal failed to come to fruition last year. Last July, Bavarian Nordic had agreed to be acquired by a consortium of private equity firms, led by Nordic Capital and Permira, for 233 kroner per share in cash.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze